Stage IV Liver Cancer


Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (May 27, 2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar®... Continue Reading

Factors Affecting Quality of Life at the End of Life (July 20, 2012)

For people with advanced cancer, quality of life at the end of life—sometimes referred to as “a good death”—may have less to do with medical treatment and more to do with a therapeutic alliance... Continue Reading

Today at 6 PM EST Watch CancerConnect Web Chat with the Experts on Liver Cancer (March 20, 2012)

Boris Kuvshinoff II, MD, MBA Treatment Options for Patients with Liver Cancer: Web Chat with Boris Kuvshinoff II, MD, MBA and Renuka Iyer, MD, March 20th at 6 PM EST Drs. Kuvshinoff and Iyer are Co-Directors... Continue Reading

CancerConnect Live Web Chat with Dr. Boris Kuvshinoff II and Dr. Renuka Iyer on Treatment Options for Patients with Liver Cancer on March 20, 2012 6 PM EST. (March 5, 2012)

Boris Kuvshinoff II, MD, MBA Treatment Options for Patients with Liver Cancer: Web Chat with Boris Kuvshinoff II, MD, MBA and Renuka Iyer, MD Drs. Kuvshinoff and Iyer are Co-Directors of the Liver... Continue Reading

Nexavar Superior to Sutent in Liver Cancer (June 23, 2011)

Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical... Continue Reading

Cabozantinib Shows Promise against Bone Metastases (May 31, 2011)

The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients.... Continue Reading

FDA Grants Orphan Drug Status to Investigational Liver Cancer Drug (May 2, 2011)

PV-10—an investigational liver cancer drug—has been designated an orphan drug by the US Food and Drug Administration (FDA). The orphan drug designation is intended to encourage the development of drugs... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival... Continue Reading

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (May 17, 2010)

According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival... Continue Reading

Sutent® Not Effective for Advanced Liver Cancer (July 10, 2009)

In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were... Continue Reading

Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma (February 3, 2009)

Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma According to the results of a Phase II clinical trial, the combination of two targeted therapies-Avastin® (bevacizumab) and... Continue Reading

Nexavar® Effective for Hepatocellular Carcinoma in Asians (January 21, 2009)

Nexavar® Effective for Hepatocellular Carcinoma in Asians Researchers from 23 medical centers in Asia have reported that Nexavar® (sorafenib) is effective in patients with advanced hepatocellular carcinoma... Continue Reading

Updates on the Management of Advanced Hepato-pancreato-biliary Malignancies (October 21, 2007)

Updates on the Management of Advanced Hepato-pancreato-biliary Malignancies: A Report from the 14th European Cancer Conference (ECCO) Introduction The 14th European Cancer Conference of the European Cancer... Continue Reading

Addition of Nexavar® to Adriamycin® Improves Survival in Hepatocellular Carcinoma (October 1, 2007)

Addition of Nexavar® to Adriamycin® Improves Survival in Hepatocellular Carcinoma According to results recently presented at the 2007 European Cancer Organization (ECCO 14), the addition of the targeted... Continue Reading

Further Evidence that Nexavar® Improves Liver Cancer Survival Among Different Ethnic Groups (August 29, 2007)

Further Evidence that Nexavar® Improves Liver Cancer Survival Among Different Ethnic Groups A Phase III clinical trial (phase prior to FDA review) comparing Nexavar® (sorafenib) to placebo has provided... Continue Reading

Nexavar® Improves Survival in Advanced Hepatocellular Carcinoma (June 6, 2007)

Nexavar® Improves Survival in Advanced Hepatocellular Carcinoma According to results from a late-breaking session presented at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO),... Continue Reading

Interferon Following Surgery May Improve Survival in Advanced Liver Cancer (May 31, 2007)

Interferon Following Surgery May Improve Survival in Advanced Liver Cancer According to an article recently published in the Annals of Surgery, administration of the immune stimulating agent interferon... Continue Reading

Study Reviews Chemotherapy for Advanced Biliary Tract Cancer (April 4, 2007)

Study Reviews Chemotherapy for Advanced Biliary Tract Cancer According to the results of a combined analysis of previously published studies, chemotherapy with a combination of Gemzar® (gemcitabine) and... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS